Vaccine selection should be based on science, not place of origin — Villanueva | Inquirer News

Vaccine selection should be based on science, not place of origin — Villanueva

/ 12:34 PM January 19, 2021

MANILA, Philippines — Selecting a Covid-19 vaccine should be based on science and not its place of origin, Senator Joel Villanueva said, adding that Chinese vaccines “are not Pogo workers that can speed through an express lane.”

“Underlying all of this is science, which is non-negotiable. Evidence-based selection. We should go where the hard science leads us,” Villanueva said in a statement Tuesday.

“When we say science then it means we do not blindly express a preference for vaccines based on its country of origin. Hindi po porke’t (Not just because) they come in packaging with Chinese characters, we express preference na kaagad (immediately) even in the absence of a review by our own scientists,” he added.

Article continues after this advertisement

Villanueva said that Chinese vaccines, unlike the Philippine offshore gaming operator (Pogo) workers, don’t have an “express lane” where they can just speed up its development.

FEATURED STORIES

“Ang Chinese vaccines sa ngayon ay hindi Pogo workers na may immigration express lane. Pero kung proven na mabisa, then let us roll out the red carpet for these vaccines,” he said.

(Chinese vaccines are not Pogo workers who have an immigration express lane. But if it’s proven that it’s effective, then let us roll out the red carpet for these vaccines.)

Article continues after this advertisement

Villanueva issued the statement following the two hearings conducted by the Senate on the government’s Covid-19 vaccination plan last week wherein senators quizzed officials over their seeming preference for China’s Sinovac vaccine.

Article continues after this advertisement

Officials, however, have repeatedly denied any preference for the vaccine developed by the Chinese firm.

Article continues after this advertisement

According to the senator, the chamber’s inquiry “not only lifted the veil of secrecy on the cost of vaccines but have also raised the bar on the kind of vaccines we must buy.”

“When we fine-tune the plan, then we are not competing but we are collaborating with the executive. When mistakes are corrected, the people win,” he said.

Article continues after this advertisement

He pointed out that the “3M rule” should be considered in vaccine selection.

“Una, Mabisa. Pangalawa, Mura o abot-kaya. Pangatlo, Makakarating agad kasi aanhin mo po ang damo kung patay na ang kabayo,” he explained.

(First, Effective. Second, Cheap or affordable. Third, it will arrive immediately because what good will it do if the ones who need it are already dead.)

The Philippine government has already secured 25 million doses of China’s Sinovac vaccine, 50,000 of which will arrive by February.

The Philippines also earlier signed a deal with the Serum Institute of India for 30 million doses of the Covovax COVID-19 vaccine, which will be available by the third quarter of 2021.

Meanwhile, 30 million doses of vaccine from British drugmaker AstraZeneca, and 25 million doses of Russia’s  Sputnik V vaccine are set to be acquired by the government.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

The Senate is scheduled to resume its vaccine plan hearing on Friday, Jan. 22. — with a report from Zac Sarao, Trainee

EDV
TAGS: coronavirus Philippines

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.